T2 Biosystems, Inc. (TTOO) Stock Price & Analysis
T2 Biosystems, Inc. (TTOO) — price $0.0006 (+50.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
T2 Biosystems, Inc. · TTOO
The company is actively developing new diagnostic candidates and operates within the highly competitive medical diagnostics industry, facing significant financial and operational challenges.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0006 | |
| Change on the day | +50.00% | |
| 52-week range | $0.0001 – $0.05 | |
| Shares traded on the day | 35 |
Price & events
Other perspectives
Council score for T2 Biosystems (TTOO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is T2 Biosystems (TTOO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. T2 Biosystems, Inc. (TTOO) is the company analyzed here. It employs 113 people and is led by Craig R. Jalbert. In Q3 FY2024 it reported revenue of $2M and net income of -$10M.
What do the latest results show for T2 Biosystems (TTOO)?
Short answer · as of
The most recent reported quarter, Q3 FY2024, carried revenue of $2M. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2024 | $2M | -$10M | -$0.57 (diluted) |
| Q2 FY2024 | $2M | -$9M | -$0.64 (diluted) |
| Q1 FY2024 | $2M | -$14M | -$2.66 (diluted) |
What are the financial strengths and risks for T2 Biosystems (TTOO)?
Short answer · as of
The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 147.3% · current ratio 0.45.
What should you watch next at T2 Biosystems (TTOO)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $33.30M · EPS -0.70 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2024) was filed Nov 14, 2024 — 18 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $33.30M
- EPS estimate
- $-0.70
Measured against a quoted price of $0.0006 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 1
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TTOO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TTOO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com